Black Diamond Therapeutics (BDTX) Current Assets (2018 - 2026)

Black Diamond Therapeutics' Current Assets history runs 9 years deep, the most recent figure standing at $123.0 million for Q1 2026.

• Quarterly Current Assets fell 21.01% year-over-year to $123.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $123.0 million (down 21.01% YoY) and the FY2025 annual result came in at $132.4 million, up 30.9% from the prior year.
• Current Assets was $123.0 million for Q1 2026 at Black Diamond Therapeutics, down from $132.4 million in the prior quarter.
• Across five years, Current Assets topped out at $188.3 million in Q1 2022 and bottomed at $93.0 million in Q2 2023.
• A 5-year average of $133.9 million and a median of $132.4 million in 2025 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2023 — Current Assets tumbled 44.83% — and 2024, when it jumped 36.31%.
• Black Diamond Therapeutics' Current Assets stood at $127.7 million in 2022, then advanced by 4.96% to $134.0 million in 2023, then dropped by 24.51% to $101.2 million in 2024, then soared by 30.9% to $132.4 million in 2025, then retreated by 7.15% to $123.0 million in 2026.
• Business Quant data shows BDTX's Current Assets at $123.0 million in Q1 2026, $132.4 million in Q4 2025, and $139.0 million in Q3 2025.